A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis. The gene discussed is AOC3; the disease is metabolic dysfunction-associated steatohepatitis.